It's only one trial, and we don't even know if the report is correct. But a leaked draft report indicated that remdesivir was ineffective in its first controlled trial. Let's assume that this is true and we see the same from other trials. If so, this will not simply be another experimental drug failing. It will be deeply disturbing. Here's why.
Preliminary data, obtained from a randomized clinical trial of remdesivir in China, look bad. Maybe even very bad. But this doesn't mean that the drug won't be shown to be useful in other trials. Nonetheless, not good news.
Remdesivir, the most promising anti-coronavirus drug at this time is no fun to synthesize. But Gilead, the drug's maker, is synthesizing a whole bunch of it. Does this tell us anything about whether the drug works? Maybe.
Early clinical trial results from Gilead show that its antiviral drug, remdesivir, has promise in treating patients with severe COVID-19. Though there are major caveats, there is good reason for cautious optimism.
The world anxiously awaits while clinical trials of remdesivir are in progress. The drug failed to stop Ebola. Does this mean it will also fail to stop coronavirus? No. According to a new study in the Journal of Biological Chemistry, the drug should work better. Here's why.
Remdesivir, an antiviral drug that many are pinning their hopes on to help solve this pandemic nightmare, is now being tested in hundreds of trials. Results are expected within weeks. But the drug has already been tested in monkeys. And it worked.
Two of the experimental coronavirus drugs, chloroquine, and hydroxychloroquine are a breeze to synthesize. But remdesivir, possibly the most promising candidate, is anything but. It's a royal pain. Here's why.
As the horror known as the coronavirus tightens its grip on the world, and a vaccine is years away, our best hope is an antiviral drug that minimizes the damage caused by coronavirus replication. New data on favipiravir, a repurposed drug originally discovered in Japan, looks promising in trials in China. But nothing is ever straightforward in drug discovery -- and that is no different here. Here's a summary of the new findings.
As the coronavirus continues to terrorize the world, people are pinning their hopes on companies that are doing vaccine and drug research to -- maybe -- get us out of this mess. Yet, many of the companies doing the work, especially Gilead Science, are "the bad guys." Except when we need them. Gilead's drug, remdesivir, is now in clinical trials in China so they're OK for now. Hypocrisy at its finest.